IQMS growing rapidly, hiring more workers in Paso Robles
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →U.K. crackdown sinks Sientra stock price
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Merged Ryland Group and Standard Pacific trading as CalAtlantic Group
CalAtlantic Group, the new homebuilding company formed in the merger between Ryland Group and Standard Pacific, traded under its new symbol CAA on Oct. 1 on the New York Stock Exchange. Now that the $5.2 billion “merger of equals” between the Westlake-based and Irvine-based homebuilders, respectively, has gone through, the new company has become the Read More →
Read More →Cal Amp’s second quarter earnings beat analyst estimates
Oxnard-based Cal Amp, which makes products for the wireless sector, beat analyst estimates on Oct. 1 when it reported second quarter 2016 results. Cal Amp posted earnings of 27 cents per share, beating analyst estimates of 26 cents per share. Analysts expected Cal Amp’s revenues to be around $68 million, but the company beat those Read More →
Read More →European regulators have good news for Amgen on cancer drugs
One of the world’s most expensive cancer drugs got conditional approval from European regulators on Sept. 25. Europeans granted Thousand Oaks-based Amgen conditional approval of its rare blood cancer drug Blincyto and gave a positive evaluation of Amgen’s multiple-myeloma drug Kyprolis. Blincyto is an immunotherapy that is designed to treat a rare form of leukemia Read More →
Read More →Amgen cancer drug Kyprolis to get expedited review from FDA
An experimental multiple myeloma treatment using Amgen’s Kyprolis will get an expedited review from the U.S. Food and Drug Administration. The FDA said it will use an expedited review process to review a multiple-myeloma treatment using Kyprolis and the genric drug dexamethasone. On July 23, Amgen submitted additional data to the FDA which compared this Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
